Which large pharma might make the next move in the VEGF bispecific race?news2025-08-15T11:00:04+00:00August 15th, 2025|Endpoints News|
Lilly gets another obesity partner in deal with Superluminal worth up to $1.3Bnews2025-08-14T12:00:30+00:00August 14th, 2025|Endpoints News|
Sarepta sells Arrowhead stake for cash and to help fulfill milestone paymentnews2025-08-14T10:58:16+00:00August 14th, 2025|Endpoints News|
PureTech spins out its IPF drug as it readies for Phase 3 meeting with the FDAnews2025-08-12T15:36:17+00:00August 12th, 2025|Endpoints News|
Bayer licenses early-stage KRAS cancer drug from Kumquat for up to $1.3Bnews2025-08-12T10:57:42+00:00August 12th, 2025|Endpoints News|
Bicycle Therapeutics lays off staff, Genentech partnership comes to an endnews2025-08-08T14:34:47+00:00August 8th, 2025|Endpoints News|
Merck was the only bidder for Verona before the $10B buyoutnews2025-08-06T14:49:23+00:00August 6th, 2025|Endpoints News|
Specialty pharma SERB to buy Y-mAbs in $412M all-cash dealnews2025-08-05T18:17:35+00:00August 5th, 2025|Endpoints News|
J&J divests from some of its incubator sitesnews2025-08-04T19:47:20+00:00August 4th, 2025|Endpoints News|
Royalty market accelerates as XOMA acquires two biotechs and OrbiMed bags another fundnews2025-08-04T15:17:39+00:00August 4th, 2025|Endpoints News|
